Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Reduced binding activity of transcription factor NF-kappa B accounts for MHC class I repression in adenovirus type 12 E 1-transformed cells.

Meijer I, Boot AJ, Mahabir G, Zantema A, van der Eb AJ.

Cell Immunol. 1992 Nov;145(1):56-65.

PMID:
1423646
2.

Co-regulated expression of junB and MHC class I genes in adenovirus-transformed cells.

Meijer I, van Dam H, Boot AJ, Bos JL, Zantema A, van der Eb AJ.

Oncogene. 1991 Jun;6(6):911-6.

PMID:
1906158
3.

Ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin.

van der Schroeff JG, Evers LM, Boot AJ, Bos JL.

J Invest Dermatol. 1990 Apr;94(4):423-5.

4.

Activated ras genes in human seminoma: evidence for tumor heterogeneity.

Mulder MP, Keijzer W, Verkerk A, Boot AJ, Prins ME, Splinter TA, Bos JL.

Oncogene. 1989 Nov;4(11):1345-51.

PMID:
2682461
5.

N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

van 't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL.

Mol Cell Biol. 1989 Jul;9(7):3114-6.

6.

Mechanisms of ras mutation in myelodysplastic syndrome.

Yunis JJ, Boot AJ, Mayer MG, Bos JL.

Oncogene. 1989 May;4(5):609-14.

PMID:
2657575
7.

Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.

Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, van Bodegom PC, Bos JL.

Cancer Res. 1988 Oct 15;48(20):5738-41.

8.

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL.

Nucleic Acids Res. 1988 Aug 25;16(16):7773-82.

Supplemental Content

Support Center